LinkedIn
WebsiteZura Bio Limited Overview
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage biotechnology company headquartered in Henderson, Nevada. Founded in 2022, the firm focuses on developing dual-pathway biologics to address immune and inflammatory disorders that may not be adequately treated by single-pathway medicines. Its pipeline includes three assets—tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880)—each designed to target specific cytokines associated with autoimmune conditions.
Corporate Structure
Zura Bio employs between 11 and 50 people across research, clinical development, and corporate functions. Key leadership includes:
- Robert Lisicki, Chief Executive Officer and Director, who has nearly 30 years of experience in the biopharmaceutical industry, including roles at Arena Pharmaceuticals and Regeneron.
- Eric Hyllengren, Chief Financial Officer, who has over 20 years of experience in corporate finance and investor relations, previously working at Atara Biotherapeutics and Amgen.
- Gary Whale, PhD, Chief Technology Officer, has over 25 years of experience in pharmaceuticals, specializing in biologics development.
Biotechnology by Sangharsh Lohakare
Recent Developments and News
On September 4, 2025, Zura Bio filed an 8-K report (Acc-no: 0001104659-25-087286) covering items 7.01 and 9.01, which typically updates investors on material events and financial conditions. On August 20, 2025, a second 8-K (Acc-no: 0001104659-25-080521) was filed, indicating further corporate disclosures. A Schedule 13G/A amendment filed on August 14, 2025, indicates that Venrock-related entities beneficially own 6,353,353 Class A Ordinary Shares, representing 9.9% of the outstanding shares.
In May 2025, Zura Bio initiated its Phase 2 TibuSHIELD trial, which evaluates tibulizumab's effects in patients with systemic sclerosis. In August 2025, the company reported its second-quarter financial results and highlighted participation in industry events including the European Academy of Dermatology and Venereology (EADV) Congress 2025 and the Cantor Fitzgerald Global Healthcare Conference in September 2025.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Stock Price (09/29/2025) | $4.3589 (+45.78%) |
| Trading Volume | 4,432,922 shares |
| 52-Week Range | $0.97 – $5.07 |
| Market Capitalization | $156.69 million |
| Average Daily Volume | 967,009 shares |
| Beta (5Y Monthly) | –0.02 |
| Price/Book (mrq) | 1.24 |
| EPS (ttm) | –0.92 |
| Net Income (ttm) | –$65.42 million |
| Total Cash (mrq) | $154.49 million |
| Levered Free Cash Flow (ttm) | –$24.32 million |
| 1-Year Target Estimate | $13.33 |
The firm’s cash reserves are close to its market capitalization, providing resources for ongoing trials. Negative EPS and net loss figures reflect the company’s investment in research and development, typical of clinical-stage biotechs. The absence of a P/E ratio indicates a lack of profitability at this stage. Shared beneficial ownership by institutional investors may influence corporate governance and strategic decisions.
Market Position and Industry Context
Zura Bio operates in the immunology and inflammation sector, where established therapies often focus on single pathways. Its dual-pathway approach aims to improve treatment efficacy by targeting multiple cytokines. The company's early-stage pipeline distinguishes it from peers within similar development stages, though it faces risks related to regulatory approvals and capital needs. As a small-cap biotech, Zura Bio is subject to stock price fluctuations influenced by clinical data outcomes and financing activities, with a one-year analyst target of $13.33 based on potential future developments.
TL;DR
On September 29, 2025, Zura Bio’s share price rose to $4.3589, an increase of 45.78% on a volume of 4.43 million shares. Institutional holdings via Schedule 13G/A total 9.9% ownership. In May 2025, the Phase 2 TibuSHIELD trial was initiated for tibulizumab, and August 2025 financial results were reported. Cash reserves amounting to $154.5 million support ongoing clinical programs, while net losses of $65.4 million reflect R&D spending. Upcoming milestones include interim data from Phase 2 trials and presentations at investor conferences in late 2025.
